INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

LIGAND PHARMACEUTICALS INC

LGNDCIK 0000886163

EDGAR filingsOpen in network
Price$299.00
1 year+57.8%
Disclosed transactions60
Buys / sells0 / 37
Max Insider Score50
Connections with evidence13

LGND · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
25
AJ
Aryeh JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$90K
282 sh
Nov 4, 2026Nov 6, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • Holds over 5% ofevidence
    Pelthos Therapeutics Inc.49.9% of class · Schedule 13D · Nov 2, 2026
  • ← Insider ofevidence
    Sabba Stephen LDirector · Jun 9, 2026
  • ← Insider ofevidence
    Haas JasonDirector · Jun 9, 2026
  • ← Insider ofevidence
traded Nov 4, 2026
+2d
SEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$162K
520 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$152K
490 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$140K
440 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

3
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$39K
120 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$87K
283 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$102K
320 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$198K
634 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$162K
522 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

3
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$25K
80 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$218K
708 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$64K
200 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$89K
280 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

2
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$261K
5,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

6
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$126K
403 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
5,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
340 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

8
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$600K
1,976 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

1
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$124K
404 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

4
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$252K
833 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

1
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$72K
235 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

0
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$5,232
17 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

0
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$18K
340 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

4
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$467K
1,535 sh
Oct 2, 2026Oct 6, 2026
traded Oct 2, 2026
+4dSEC FORM 4

Evidence

5
ZM
Zimmermann MartineDirector
LGNDLIGAND PHARMACEUTICALS INC
Tax withholding
F$34K
115 sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

40
ZM
Zimmermann MartineDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$342K
1,200 sh
Sep 10, 2026Sep 14, 2026
traded Sep 10, 2026
+4dSEC FORM 4

Evidence

12
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$116K
400 sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

12
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$111K
385 sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

19
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$606K
2,115 sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

12
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$85K
300 sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

15
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$513K
1,800 sh
Sep 3, 2026Sep 8, 2026
traded Sep 3, 2026
+5dSEC FORM 4

Evidence

10
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$855K
16.2K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
16.2K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
7,171 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
2,074 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

5
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
6,138 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

43
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$2.09M
7,138 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

23
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$316K
6,138 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
3,348 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
2,869 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

24
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$9.24M
31.6K sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$230K
3,348 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

2
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$410K
7,171 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$160K
2,869 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

0
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$145K
2,074 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

7
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$190K
600 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

18
DC
Davis Todd CDirector, Chief Executive Officer
LGNDLIGAND PHARMACEUTICALS INC
Other acquisition or disposition
J$21K
132 sh
Jun 30, 2026Jul 6, 2026
traded Jun 30, 2026
+6dSEC FORM 4

Evidence

11
EO
Espinoza OctavioChief Financial Officer
LGNDLIGAND PHARMACEUTICALS INC
Other acquisition or disposition
J$2,732
17 sh
Jun 30, 2026Jul 6, 2026
traded Jun 30, 2026
+6dSEC FORM 4

Evidence

7
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$219K
700 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

2
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M—
5,000 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

10
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$349K
1,119 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

4
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$32K
104 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

4
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$31K
100 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

7
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$122K
396 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

8
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Option exercise · 10b5-1 plan
M$261K
5,000 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

1
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Other acquisition or disposition · 10b5-1 plan
J$21K
132 sh
Jun 30, 2026Jul 6, 2026
traded Jun 30, 2026
+6dSEC FORM 4

Evidence

10
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$284K
900 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

10
RA
Reardon AndrewCLO & Secretary
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale · 10b5-1 plan
SELL$338K
1,081 sh
Jul 1, 2026Jul 6, 2026
traded Jul 1, 2026
+5dSEC FORM 4

Evidence

50
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$886K
3,461 sh
Jun 12, 2026Jun 15, 2026
traded Jun 12, 2026
+3dSEC FORM 4

Evidence

20
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$155K
3,000 sh
Jun 12, 2026Jun 15, 2026
traded Jun 12, 2026
+3dSEC FORM 4

Evidence

Zimmermann Martine
Director · Jun 9, 2026
  • ← Disclosed trade inevidence
    Gilbert Ray Cisneros, Jr.Purchase disclosed 2026-06-08 · Jun 8, 2026
  • ← Insider ofevidence
    Reardon AndrewCLO & Secretary · Feb 18, 2026
  • ← Insider ofevidence
    Espinoza OctavioChief Financial Officer · Dec 9, 2025
  • ← Insider ofevidence
    Aryeh JasonDirector · Dec 8, 2025
  • ← Insider ofevidence
    Davis Todd CDirector, Chief Executive Officer · Dec 8, 2025
  • ← Insider ofevidence
    Gray Nancy RyanDirector · Nov 12, 2025
  • ← Insider ofevidence
    Lamattina John LDirector · Nov 12, 2025
  • ← Insider ofevidence
    Kozarich John WDirector · Nov 5, 2025

    • Planned sales and 5% stakes

    Form 144, 13D and 13G
    • AJAryeh JasonDirector · sale around Nov 4, 2026 · 282 shares$90KForm 144 · filed Nov 4, 2026
    • AJAryeh JasonDirector · sale around Nov 2, 2026 · 700 shares$222KForm 144 · filed Nov 2, 2026
    • AJAryeh JasonDirector · sale around Oct 30, 2026 · 202 shares$65KForm 144 · filed Oct 30, 2026
    • JAJASON M ARYEHDirector · sale around Oct 30, 2026 · 1,209 shares$385KForm 144 · filed Oct 30, 2026